Camlin Fine Sciences Limited (CFSL) has successfully resolved technical challenges at its vanillin manufacturing plant and is now positioned to capitalize on tight global market conditions. The company's current market price stands at ₹154.55 against a target price of ₹480.00.

Vanillin Plant Operations Stabilize

CFSL's vanillin plant, commissioned in January 2023, experienced a prolonged startup phase due to technical issues including colour inconsistency and chlorine contamination. These challenges delayed commercial sales until H2-CY24, but the company has now resolved these operational problems and begun commercial production.

Global Market Dynamics Favor CFSL

The global vanillin market presents favorable conditions for CFSL, particularly in its key target markets of Europe and the United States. These regions consume approximately 14,000 tonnes per annum of high-quality Solvay-grade vanillin.

Several factors have created meaningful supply gaps in these markets:

• Limited local manufacturing capacity
• Gradual restart of Solvay's previously mothballed production facilities
• Elimination of Chinese imports following punitive anti-dumping duties

These market conditions structurally benefit non-Chinese suppliers like CFSL, with US spot prices expected to rise from current levels of $20-22 per kg to over $32 per kg by H2-CY26F.

Diversified Product Portfolio

CFSL operates across multiple product categories with its comprehensive blend portfolio:

• Xtendra: Synthetic antioxidants
• Nasure: Natural, plant-based antioxidants
• Ezential: High-value functional blends

The company's product offerings are characterized by rising formulation complexity, application specificity, and increasing entry barriers, which strengthen its competitive positioning.

Strategic Expansion Through Vinpai Acquisition

The Vinpai acquisition has strategically transformed CFSL into a global clean-label and natural solutions platform. This acquisition provides access to approximately 3,000 products across diverse industry segments:

• Dairy additives
• Flavours and texturisers
• Emulsifiers
• Nutraceuticals
• Cosmetics
• Medical alginates

This expansion significantly broadens CFSL's market reach and positions the company as a comprehensive solutions provider in the natural and clean-label ingredients space.

Camlin Fine Sciences Limited has issued a formal response to BSE Limited regarding a surveillance inquiry about increased trading volume in the company's shares. The response, dated January 8, 2026, addresses concerns raised by the stock exchange's surveillance department.

Company's Regulatory Compliance Position

The company emphasized its commitment to regulatory transparency, stating that it has consistently informed stock exchanges about all relevant events and information as mandated under Regulation 30 of the SEBI (LODR) Regulations, 2015. These disclosures cover events that may impact the company's operations or performance.

Response to Volume Inquiry

Camlin Fine Sciences clarified its position regarding the ability to comment on share price and volume movements. The company stated that since its equity shares are freely traded on stock exchanges, it cannot provide commentary on the movement in price or volume of its equity shares.

Key Communication Details

The response was digitally signed by Rahul Sawale, who serves as Company Secretary and VP Legal for Camlin Fine Sciences Limited. The communication was addressed to BSE Limited's surveillance department at their Dalal Street office in Mumbai.

Regulatory Framework Context

The inquiry falls under standard stock exchange surveillance procedures, where exchanges monitor unusual trading patterns and seek clarifications from listed companies. Companies are required to disclose material information that could affect their share prices, but they typically cannot comment on market-driven trading activities beyond their control.